Business Context and Reporting Period
Company: Ovid Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2019
Reporting Period: Specific event date of February 20, 2019.
Context: The filing announces the designation of Series A Convertible Preferred Stock and the execution of underwriting agreements for a concurrent public offering of common and preferred stock.
Key Financial Metrics
This filing does not contain audited financial statements, revenue, profit, cash flow, or margin data. The primary financial metrics disclosed relate to the capital raise:
- Expected Gross Proceeds: Approximately $30 million (before underwriting discounts and expenses).
- Common Stock Offering: 12,500,000 shares at $2.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,750,000 additional common shares at $2.00 per share.
- Preferred Stock Offering: 2,500 shares of Series A Convertible Preferred Stock at $2,000 per share.
- Conversion Rate: Each Series A share converts into 1,000 shares of Common Stock.
- Liquidation Preference: $0.001 per share of Series A Stock (senior to common stock).
Material Changes
The filing details significant corporate actions taken on February 20, 2019:
- Capital Structure Amendment: Filed a Certificate of Designation for Series A Convertible Preferred Stock with the Delaware Secretary of State.
- Beneficial Ownership Limitations: Holders of Series A Stock are generally prohibited from converting if it results in ownership exceeding 9.99% of outstanding common stock, unless the holder elects to increase this limit to up to 19.99% with 61 days' notice.
- Lock-Up Agreements: All directors, executive officers, and their affiliates have agreed not to sell common stock for 90 days following February 20, 2019. The Company has also agreed to a 90-day lock-up on its own common stock sales.
Guidance, Outlook, and Risks
Outlook and Closing: The offerings are expected to close on or about February 22, 2019, subject to customary closing conditions. The offering is being made pursuant to a Form S-3 registration statement declared effective on June 19, 2018.
Risks and Contingencies:
- Closing Conditions: Proceeds are contingent on the satisfaction of customary closing conditions.
- Underwriting Terms: The agreements contain customary representations, warranties, and indemnification obligations. These were made solely for the benefit of the parties to the agreement.
- Voting Rights: Series A Stock generally has no voting rights except as required by law or to amend the terms of the Series A Stock.
Investor Verification Checklist
- Verify the final closing date of the offerings (expected February 22, 2019) and the actual net proceeds received after underwriting discounts.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific details on dividend rights and liquidation preferences beyond the summary provided.
- Confirm whether the underwriters exercised the 1,750,000 share over-allotment option within the 30-day window.
- Check subsequent filings for the use of proceeds and any changes to the Company's cash position post-offering.